Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease [1]

Mayo Clinic Proceedings

Volumn 82, Issue 7, 2007, Pages 888-

  Myerson, Merle ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPOPROTEIN; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE MARKER; HEART INFARCTION; HUMAN; INFLAMMATION; LETTER; PREDICTION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STROKE;

EID: 34347332211     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.7.888     Document Type: Letter

References (4)

1. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159-165.
2. 2 and risk stratification for cardiovascular disease: not ready for "prime time" [editorial]. Mayo Clin Proc. 2007;82:155-157.
3. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) Study. Arch Intern Med. 2005;165:2479-2484.
4. Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006 Summer;9:138-143.